EZH2 Inhibition Compromises α4-1BB-Mediated Antitumor Efficacy by Reducing the Survival and Effector Programming of CD8(+) T Cells

Enhancer of Zeste Homolog 2 (EZH2) inhibitors (EZH2i) are approved to treat certain cancer types. Previous studies have suggested the potential to combine EZH2i with immune checkpoint blockade targeting coinhibitory receptors like PD-(L)1 and CTLA-4, but whether it can also enhance the activity of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Stairiker, Christopher J., Pfister, Sophia Xiao, Hendrickson, Eleanore, Yang, Wenjing, Xie, Tao, Lee, Catherine, Zhang, Haikuo, Dillon, Christopher, Thomas, Graham D., Salek-Ardakani, Shahram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683156/
https://www.ncbi.nlm.nih.gov/pubmed/34925340
http://dx.doi.org/10.3389/fimmu.2021.770080

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683156/
https://www.ncbi.nlm.nih.gov/pubmed/34925340
http://dx.doi.org/10.3389/fimmu.2021.770080

Ejemplares similares